Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
Faraday Pharmaceuticals has raised $52.8M in total funding. The most recent round was Series C. The last funding was announced in November 2022.
Faraday Pharmaceuticals's investors include ARCH Venture Partners, Polaris Partners, OUP (Osage University Partners), Alexandria Real Estate Equities, Washington Research Foundation.
Faraday Pharmaceuticals is headquartered in Seattle, United States.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury.
Faraday Pharmaceuticals is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Faraday Pharmaceuticals — Funding & Investors." VCBacked, November 7, 2022, https://www.vcbacked.co/company/faraday-pharmaceuticals. Accessed August 14, 2026.
VCBacked. (2022). Faraday Pharmaceuticals — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/faraday-pharmaceuticals
{{cite web |title=Faraday Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/faraday-pharmaceuticals |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated